Keywords
How to Cite
Abstract
Objective: To describe the factors related to chemical phlebitis in patients diagnosed with cancer undergoing chemotherapeutic treatment. Methodology: A systematic review of the literature was carried out, according to recommendations of Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA). Results: The factors that increase the risk of chemical phlebitis were: age older than 57 years, female sex, history of cancer, metastatic disease, arterial hypertension, neutropenia, smoking, lymph node emptying, hypoalbuminemia, use of cytotoxic drugs, epirubicin, fosaprepitant, anthracycline and vinorelbine, premixed presentation, dilution in 50 cc of Normal Saline Solution, administration time greater than 60 minutes, catheters of large gauges such as 18 G or 20 G and anatomical location of the catheter in the forearm or antecubital fossa. Conclusion: Factors related to chemical phlebitis found in the literature were features inherent to the patient and their treatment. Therefore, some of these are not modifiable.
References
Santiago-Valverde ME. Relación entre conocimiento y práctica sobre cateterismo venoso periférico en los enfermeros de hospitalización de medicina general del Hospital Nacional Hipólito UNANUE. Rev Peru Obstet Enferm. [Internet]. 2012; 8(1): 10–22.
Bulechek GL, Butcher HK, Dochterman JM. CMW. Clasificación de Intervenciones de Enfermería (NIC). Madrid: Elsevier; 2013.
Athanasio Johann D, Reichembach Danski MT, Adami Vayego S, Aparecida Barbosa D, Lind J. Factores de riesgo para complicaciones en el catéter periférico en adultos: análisis secundario de ensayo clínico aleatorizado. Rev Lat Am Enfermagem. 2016; 24: e2833. doi: https://doi.org/10.1590/1518-8345.1457.2833
Gorski L, Hadaway L, Hagle ME, McGoldrick M, Orr M, Doellman D. Infusion therapy standards of practice [Internet]. J Infus Nurs. 2016; 39(1S) Suppl Jan/Feb: 169 .
National Cancer Institute, National Institutes of Health, Departement of Health & Human Services - USA. The NCI Consumers’ Cancer Dictionary for peer review [Internet]. Bethesda (MD): 2009; 79 p.
Becerra ÁG, Moreno Pinilla LE, Sarmiento Hernández S. Evaluación del procedimiento de administración de medicamentos endovenosos y la presencia de flebitis química en el servicio de hospitalización de la Clínica Foscal Internacional durante el año 2015 [Internet]. Medellín: Universidad CES; 2015. Recuperado de: https://repository.ces.edu.co/handle/10946/593
Alonso Delgado L, García Díaz M, González Andrés M. Gestión de calidad en la prevención de flebitis en el servicio de Oncología del HUBU [Internet]. Burgos: Universidad de Burgos. 2017. p. 37. Recuperado de: https://riubu.ubu.es/handle/10259/4418
Rojas-Sánchez LZ, Parra DI, Camargo-Figuera FA. Incidencia y factores asociados al desarrollo de flebitis: resultados del estudio piloto de una cohorte. Rev Enferm Ref. 2015; IV(4): 61–67. doi: http://dx.doi.org/10.12707/RIII13141
Núñez Crespo FJ. Efectos adversos hospitalarios en dispositivos venosos periféricos: Estudio de validez diagnóstica [Internet]. Madrid: Universidad Rey Juan Carlos; 2014. Recuperado de: https://burjcdigital.urjc.es/handle/10115/12299
Reichembach M, Athanasio J, Adami V, Paulo S. Complicações relacionadas ao uso do catéter venoso periférico: ensaio clínico randomizado. Acta Paul Enferm. 2016; 29(1): 84–92. doi: https://doi.org/10.1590/1982-0194201600012
Vaca Auz J, Muñoz Navarro P. Eventos adversos relacionados con los cuidados de enfermería en el Hospital de Ibarra, provincia de Imbabura. Enferm. investig [Internet]. 2016; 1(3): 102–106.
Díaz-Ríos GV, Quispe-Cóndor SZ, Sovero-Torres YM, Pando-Berrocal AK. Flebitis: incidencia y factores asociados en pacientes oncológicos. Rev Cienc Art Enferm. 2019; 4(1–2): 6–11. doi:
https://doi.org/10.24314/rcae.2019.v4n1.02
Pires Nobre AS, da Silva Martins MD. Prevalência de flebite da venopunção periférica: fatores
associados. Rev Enferm Ref. 2018; IV(16): 127–138. doi: https://doi.org/10.12707/RIV17058
Velázquez-Mendoza S, Gómez-Alonso C, Cuamatzi-Peña MT, Izquierdo-Puente MI. Conocimiento y criterios de enfermería para evitar flebitis en neonatos con catéter venoso periférico. Rev Enferm Inst Mex Seguro Soc [Internet]. 2009; 17(3): 143–147.
Lv L, Zhang J. The incidence and risk of infusion phlebitis with peripheral intravenous catheters: A meta-analysis. J Vasc Access. 2020; 21(3): 342–349. doi: https://doi.org/10.1177/1129729819877323
Contreras Carpio SM. Factores cognitivos, físicos y químicos asociados con la presencia de flebitis en pacientes atendidos por enfermeros HNERM – 2012 [Internet]. Lima: Universidad Nacional Mayor de San Marcos; 2015. Recuperado de: https://pesquisa.bvsalud.org/portal/resource/pt/biblio-871173
Urbanetto JS, Freitas APC, Oliveira APR, Santos JCR, Muniz FOM, Silva RM, et al. Risk factors
for the development of phlebitis: an integrative review of literature. Rev Gaúcha Enferm. 2017; 38(4): e57489. doi: https://doi.org/10.1590/1983-1447.2017.04.57489
Monteros Cocios GM, González Cartuche DV. Flebitis por manejo de catéter venoso periférico en pacientes atendidos en el área de quimioterapia del hospital de Solca Loja [Internet]. Loja: Universidad Nacional de Loja; 2015. Recuperado de: https://dspace.unl.edu.ec/jspui/handle/123456789/11729
Navarrete Ruíz MA. Factores que influyen en la aparición de flebitis química en pacientes hospitalizados en el área de oncología del hospital de Especialidades FF.AA. No1, octubre 2018-abril 2019 [Internet]. Universidad “Técnica de Babahoyo”; 2019. Recuperado de: http://dspace.utb.edu.ec/handle/49000/5835
Alcalde Berganza M. Flebitis en catéter venoso periférico: Factores de riesgo y prevención [Internet]. Bilbao: Universidad del País Vasco; 2017. Recuperado de: https://addi.ehu.es/bitstream/handle/10810/22537/ALCALDE_MARÍA_FLEBITIS_TFG.pdf?sequence=1
Ministerio de salud y protección social de Colombia. Evaluación de la frecuencia de eventos adversos y monitoreo de aspectos claves relacionados con la seguridad del paciente [Internet]. Vol. 2, Paquetes instruccionales Guía Técnica “Buenas Prácticas para la seguridad del paciente en la atención en salud.” Bogotá: Minsalud; 2014. Recuperado de: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/CA/Monitorearaspectos-claves-seguridad-paciente.pdf
Ministerio de Salud y Protección Social de Colombia. Seguridad del paciente y la atención segura [Internet]. Bogotá: Minsalud; 2014.Recuperado de: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/CA/Guiabuenas-practicas-seguridad-paciente.pdfcuentadealtocosto.org/site/publicaciones/situaciondel-cancer-en-la-poblacion-adulta-atendida-en-elsgsss-de-colombia-2020/
Guillén Ponce C, Molina Garrido MJ. Qué es, cómo funciona y tipos de quimioterapia [Internet]. Madrid: Sociedad Española de Oncología Médica; 2019. p. 20. Recuperado de: https://seom.org/guiaactualizada-de-tratamientos/que-es-como-funcionay-tipos-de-quimioterapia?showall=1
Fondo Colombiano de Enfermedades de Alto Costo, (CAC) C de AC. Situación del cáncer en la población adulta atendida en el SGSSS de Colombia 2020 [Internet]. Bogotá: Cuenta de Alto Costo; 2021. 332 p. Recuperado de: https://cuentadealtocosto.org/site/publicaciones/situaciondel-cancer-en-la-poblacion-adulta-atendida-en-elsgsss-de-colombia-2020/
American Cancer Society. Cancer Treatment and Survivorship Facts and Figures 2019-2021 [Internet]. Atlanta: American Cancer Society; 2019. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-andstatistics/cancer-treatment-and-survivorship-factsand-figures/cancer-treatment-and-survivorshipfacts-and-figures-2019-2021.pdf
American Cancer Society. Cancer Facts & Figures 2020 [Internet]. Atlanta: American Cancer Society; 2020. Available from: https://www.cancer.org/content/dam/cancer-rg/research/cancer-facts-andstatistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf
Ferreiro J, García JL, Barceló R, Rubio I.Quimioterapia: efectos secundarios. Gac Medica Bilbao. 2003; 100: 69–74. doi: https://doi.org/10.1016/S0304-4858(03)74432-1%0A
Ruíz-Morales ÁJ, Gómez-Restrepo C. Epidemiología Clínica. 2a ed. Bogotá: Panamericana; 2015.
Guirao Goris SJA. Utilidad y tipos de revisión de literatura. Ene. 2015; 9(2): 14. doi: https://doi.org/10.4321/s1988-348x2015000200002
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ. 2009; 339: b2535. doi: http://dx.doi.org/10.1136/bmj.b2535
Estarli M, Aguilar Barrera ES, Martínez-Rodríguez R, Baladia E, Duran Agüero S, Camacho S, et al. Ítems de referencia para publicar Protocolos de revisiones sistemáticas y metaanálisis: Declaración PRISMA-P 2015. Rev Esp Nutr Hum Diet. 2016; 20(2): 148. doi: https://doi.org/10.14306/renhyd.20.2.223
Grant MJ, Booth A. A typology of reviews: An analysis of 14 review types and associated methodologies. Health Info Libr J [Internet]. 2009; 26(2): 91–108. doi: https://doi.org/10.1111/j.1471- 1842.2009.00848.x
Yamada T, Egashira N, Watanabe H, Nagata K, Yano T, Nonaka T, et al. Decrease in the vinorelbineinduced venous irritation by pharmaceutical intervention. Support Care Cancer. 2012; 20(7): 1549–1553. doi: https://doi.org/10.1007/s00520-011-1244-3
Arias-Fernández L, Suérez-Mier B, Martínez-Ortega M del C, Lana A. Incidence and risk factors of phlebitis associated to peripheral intravenous catheters. Enfermería Clínica (English Ed). 2017; 27(2): 79–86. doi: http://dx.doi.org/10.1016/j.enfcle.2016.07.002
Leal AD, Kadakia KC, Looker S, Hilger C, Sorgatz K, Anderson K, et al. Fosaprepitantinduced phlebitis: A focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer. 2014; 22(5): 1313–1317. doi: https://doi.org/10.1007/s00520-013-2089-8
Hegerova LT, Leal AD, Grendahl DC, Seisler DK, Sorgatz KM, Anderson KJ, et al. An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2015; 23: 55–9. doi: https://doi.org/10.1007/s00520-014-2326-9
Roberts R, Hanna L, Borley A, Dolan G, Williams EM. Epirubicin chemotherapy in women with
breast cancer: Alternating arms for intravenous administration to reduce chemical phlebitis. Eur J Cancer Care (Engl). 2019; 00: e13114. doi: https://doi.org/10.1111/ecc.13114
Gonçalves SC, Sanches SM, Bueno CT, Villela de Castro DL, Damascena A, Santos GRC. Incidence of infusion site reactions in peripheral fosaprepitant infusions. J Infus Nurs. 2017; 40(6): 380–3. doi: https://doi.org/10.1097/NAN.0000000000000252
Capucho Rodrigues C, Guilherme C, Lobo da Costa Júnior M, Campos de Carvalho E. Fatores de risco para trauma vascular durante a quimioterapia antineoplásica: contribuições do emprego do risco relativo. Acta Paul Enferm. 2012; 25(3): 448–452. doi: https://doi.org/10.1590/s0103-21002012000300020
Nagata K, Egashira N, Yamada T, Watanabe H, Yamauchi Y, Oishi R. Change of formulation decreases venous irritation in breast cancer patients receiving epirubicin. Support Care Cancer. 2012; 20(5): 951–955. doi: https://doi.org/10.1007/s00520-011-1166-0
Wang J, Zheng R, Wang Z, Yang Y, Wang M, Zou W. Efficacy and safety of vinorelbine plus cisplatin vs. gemcitabine plus cisplatin for treatment of metastatic triple-negative breast cancer after failure with anthracyclines and taxanes. Med Sci Monit. 2017; 23: 4657–4664. doi: https://doi.org/10.12659/MSM.905300
Mestre Roca G, Berbel Bertolo C, Tortajada Lopez P, Gallemi Samaranch G, Aguilar Ramirez MC, Caylà Buqueras J, et al. Assessing the influence of risk factors on rates and dynamics of peripheral vein phlebitis: An observational cohort study. Med Clin (Barc). 2012; 139(5): 185–191. doi: https://doi.org/10.1016/j.medcli.2011.12.021
Wallis MC, McGrail M, Webster J, Marsh N, Gowardman J, Playford EG, et al. Risk factors for peripheral intravenous catheter failure: A multivariate analysis of data from a randomized controlled trial. Infect Control Hosp Epidemiol. 2014; 35(1): 63–68. doi: https://doi.org/10.1086/674398
Mandal A, K R. Study on incidence of phlebitis following the use of pherpheral intravenous catheter. J Fam Med Prim Care. 2019; 8: 2827–2831. doi: https://doi.org/10.4103/jfmpc.jfmpc_559_19
Nyika ML, Mukona D, Zvinavashe M. Factors Contributing to Phlebitis among Adult Patients Admitted in the Medical-Surgical Units of a Central Hospital in Harare, Zimbabwe. J Infus Nurs. 2018; 41(2): 96–102. doi: https://doi.org/10.1097/ NAN.0000000000000265
Milutinović D, Simin D, Zec D. Risk factor for phlebitis: A questionnaire study of nurses’ perception. Rev Lat Am Enfermagem. 2015; 23(4): 677–684. doi: https://doi.org/10.1590/0104-1169.0192.2603
do Rego Furtado LC. Incidence and predisposing factors of phlebitis in a surgery department. Br J Nurs. 2011; 20(14): S16–25. doi: https://doi.org/10.12968/bjon.2011.20.sup7.s16
Atay S, Sen S, Çukurlu D. Phlebitis-related peripheral venous catheterization and the associated risk factors. Niger J Clin Pract. 2018; 21: 827–831. doi: https://doi.org/10.4103/njcp.njcp_337_17
Saito H, Yoshizawa H, Yoshimori K, Katakami N, Katsumata N, Kawahara M, et al. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: A multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol. 2013; 24: 1067–1073. doi: https://doi.org/10.1093/annonc/mds541
Yamasaki M, Kimura R, Mayahara S, Maeda Y, Takahashi M, Nishida T, et al. Study on the infusionsite adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant. Mol Clin Oncol. 2019; 11(1): 43–49. doi: https://doi.org/10.3892/mco.2019.1849
Pires Nobre AS, Da Silva Martins MD. Prevalence of peripheral intravenous catheter-related phlebitis: associated factors. Rev Enferm Ref. 2018; IV(16): 127–138. doi: https://doi.org/10.12707/RIV17058
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2022 Luz Omaira Gómez-Tovar, Lizeth Sierra-Calderón, Viviana Millán-Quijano, Jennifer Becerra-Orozco